Effects of Candesartan cilexetil in patients with systemic hypertension

American Journal of Cardiology

Volumn 82, Issue 8, 1998, Pages 961-965

  Reif, Max ^a   White, William B ^a   Fagan, Timothy C ^a   Oparil, Suzanne ^a   Flanagan, Terry L ^a   Edwards, Dianne T ^a   Cushing, Daniel J ^a   Michelson, Eric L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; DRUG SAFETY; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; REGRESSION ANALYSIS; TETRAZOLES; TREATMENT OUTCOME;

EID: 0032532076     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00627-4     Document Type: Article

References (7)

1. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl Med 1996;334:1649-1654.
2. Gavras I, Gavras H. Angiotensin II - possible adverse effects on arteries, heart, brain, and kidney: experimental, clinical, and epidemiological evidence. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. Vol. 1. Biochemistry/Physiology. London: Gower Medical Publishing, 1993:40.1-40.11.
3. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995;11(suppl F):13F-19F.
4. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. Pharmacological profile of a highly potent and longacting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazol e-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7- carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-120.
5. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Human Hypertens 1997;11(suppl 2): S9-S18.
6. 14C-candesartan cilexetil in healthy volunteers. J Human Hypertens 1997;11(suppl 2):S27-S28.
7. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Human Hypertens 1997;11(suppl 2):S49-S53.